Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5142691 | 0.87 | ALDH1A1 (0.73) | SMN1; SMN2MAPK1LMNAPOLBALDH1A1 | |
| SCHEMBL8278813 | 0.86 | LMNA (0.78) | SMN1; SMN2MAPK1LMNAPOLBALDH1A1 | |
| SCHEMBL11036486 | 0.84 | ALDH1A1 (0.65) | SMN1; SMN2MAPK1LMNAPOLBALDH1A1 | |
| SCHEMBL3798756 | 0.84 | ALDH1A1 (0.64) | SMN1; SMN2MAPK1LMNAPOLBALDH1A1 | |
| SCHEMBL10788231 | 0.83 | LMNA (0.89) | SMN1; SMN2MAPK1LMNAPOLBHDAC3 | |
| SCHEMBL2605739 | 0.83 | LMNA (0.61) | SMN1; SMN2MAPK1LMNAPOLBALDH1A1 | |
| SCHEMBL30831938 | 0.83 | CDK2 (0.69) | SMN1; SMN2MAPK1LMNAPOLBALDH1A1 | |
| SCHEMBL19538968 | 0.83 | CYP3A4 (0.60) | SMN1; SMN2MAPK1LMNAPOLBALDH1A1 | |
| SCHEMBL14873232 | 0.83 | ALDH1A1 (0.63) | SMN1; SMN2MAPK1LMNAPOLBALDH1A1 | |
| SCHEMBL17968065 | 0.83 | NOTUM (0.63) | SMN1; SMN2MAPK1LMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101611005-A | Be used as the acetophenones of the replacement of PDE4 inhibitor | LEO PHARMA AS (DK) | 2009-12-23 | — | — | CN | claimed |
| CN-1902185-A | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-01-24 | — | — | CN | claimed |
| US-20250346922-A1 | COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION | TENAYA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12201617-B2 | HDAC6 inhibitors for treatment of metabolic disease and HFpEF | TENAYA THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240252502-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | TENAYA THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| WO-2024126777-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024050825-A1 | COMPOUNDS AS MLKL INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024026338-A1 | N-HETEROCYLIC GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023226965-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | TENAYA THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| EP-1784393-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| WO-2006028904-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-16 | — | — | WO | disclosed |
| CN-1656084-A | Hydroxymorpholone derivative and medical application thereof | SENJU PHARMA CO (JP) | 2005-08-17 | — | — | CN | disclosed |
| WO-2001092226-A1 | HETEROCYCLIC ANALGESIC COMPOUNDS AND METHOD OF USE THEREOF | SEPRACOR, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381148-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | HDAC6, HDAC1, HDAC2 | SMN1; SMN2 1163/4885MAPK1 1965/4885LMNA 2136/4885 |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | SMN1; SMN2 3865/4885MAPK1 1600/4885LMNA 3433/4885 |
| US-20070105890-A1 | Novel condensed imidazole derivative | DPP4, DPP7, DPP3 | SMN1; SMN2 3321/4885MAPK1 1257/4885LMNA 4616/4885 |
| US-20240252502-A1 | HDAC6 INHIBITORS FOR TREATMENT OF METABOLIC DISEASE AND HFPEF | HDAC6, HDAC1, HDAC2 | SMN1; SMN2 1163/4885MAPK1 1965/4885LMNA 2136/4885 |
| US-12201617-B2 | HDAC6 inhibitors for treatment of metabolic disease and HFpEF | HDAC6, HDAC1, HDAC2 | SMN1; SMN2 1163/4885MAPK1 1965/4885LMNA 2136/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | SMN1; SMN2 4559/4885MAPK1 832/4885LMNA 710/4885 |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | SMN1; SMN2 4559/4885MAPK1 832/4885LMNA 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.